Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I study of DK049 in tumour patients

Next Previous
Trial Profile

Phase I study of DK049 in tumour patients

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DK 049 (Primary)
  • Indications Tumours
  • Focus Adverse reactions
  • Sponsors LadRx Corporation

Most Recent Events

  • 09 Jan 2024 According to LadRx Corporation media release, the company has produced sufficient amount of LADR-7 under Good Manufacturing Practices (GMP) to initiate this study.
  • 09 Jan 2024 According to LadRx Corporation media release, the company plans to fill IND to FDA FDA by the end of the third quarter of 2024 or the beginning of the fourth quarter of 2024 and first-patient dosing with LADR-7 by the end of 2024.
  • 05 Jan 2016 According to CytRx media release, DK049 is expected to enter clinical trials in 2016.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top